Last updated: February 12, 2026
Key Insights for Biopharmaceutical Patents in Hong Kong
What Are the Patentability Criteria for Biopharmaceuticals in Hong Kong?
Hong Kong adopts a patent system aligned with the European Patent Convention (EPC). To secure a patent, an invention must satisfy the following:
-
Novelty: The invention must not have been disclosed publicly before the filing date. Public disclosures include scientific publications, presentations, or prior patents. For biopharmaceuticals, disclosures through academic papers or conference presentations can jeopardize novelty unless sufficiently anonymized or unpublished.
-
Inventive Step: The invention must not be obvious to a person skilled in the field. For biopharmaceuticals, this often requires demonstrating unexpected properties, advantages, or structural features distinguishing it from prior art.
-
Industrial Applicability: The invention must be capable of being used in some kind of industry, including pharmaceuticals. Demonstrating the ability to produce or utilize the biopharmaceutical component suffices.
-
Patentable Subject Matter: Methods of medical treatment, certain diagnostic methods, or regulatory-approved uses may be excluded from patentability, consistent with EPC standards.
Exclusions: Under Hong Kong law, certain biotechnological inventions face limitations, such as methods relating to surgical or therapeutic treatments performed on the human or animal body, which are not patentable.
How Enforceability Is Determined for Biopharmaceutical Patents?
Hong Kong’s enforcement relies on the clarity and scope of the granted patent:
-
Patent Clarity: Claims must be clear and supported by the description. Ambiguous or overly broad claims risk being invalidated or rendered unenforceable.
-
Definiteness of Claims: The claims should define the invention precisely. For biopharmaceuticals, this includes specific molecular structures, sequences, or methods of production.
-
Lack of Prior Art: Enforceability is compromised if the alleged infringement can be demonstrated to involve prior disclosures or invalidates the patent's novelty or inventive step.
-
Customs and Civil Litigation: Enforcement occurs through civil court proceedings, where the patent owner must prove infringement and the patent's validity.
What Is the Scope of Claims for Biopharmaceutical Patents?
Hong Kong patents tend to have broad claims, provided they are sufficiently supported:
-
Product Claims: Cover specific molecules, compositions, or formulations, including DNA, proteins, or small molecules.
-
Method Claims: Cover specific processes, such as methods of producing, administering, or using biopharmaceuticals.
-
Use Claims: Cover new therapeutic uses of known products, provided these uses are novel and inventive.
-
Claims Limitations: Claim scope is limited by disclosure requirements and must avoid claiming unsubstantiated or overly broad functionalities.
Policy and Practical Considerations
-
Biotechnology and biopharmaceutical innovations in Hong Kong benefit from explicit disclosure practices, including detailed descriptions of molecular structures, sequences, and production processes.
-
The patent office emphasizes that claims should be directly supported by the disclosure to withstand validity challenges.
-
Given the increasingly complex nature of biopharmaceutical inventions, claims that specify particular molecular sequences or production techniques tend to be more enforceable and less vulnerable to invalidation.
Summary of Patent Office Practices
| Criterion |
Key Points |
References |
| Patentability |
Requires novelty, inventive step, industrial applicability |
[1] |
| Enforceability |
Clarity, support, specificity in claims |
[2] |
| Scope of Claims |
Broad if supported; includes product, process, use |
[3] |
Key Takeaways
- Hong Kong aligns with EPC standards for patentability, with specific limitations on biotechnological inventions.
- Patent applications must demonstrate clear novelty, inventive step, and industrial applicability.
- Enforceability depends on well-defined, properly supported claims.
- Claims that specify molecular features or production methods tend to have stronger enforceability.
- The scope for biopharmaceutical patents is broad but constrained by disclosure support and statutory exclusions.
FAQs
1. Does Hong Kong require a local inventor for patent filing?
No. Applications can be filed by foreign applicants; however, the applicant must appoint a local patent agent.
2. How long does a biopharmaceutical patent application typically take in Hong Kong?
Approximately 3 to 4 years from filing to grant, depending on examination delays.
3. Are there specific guidelines for biotech patent applications?
Yes. The Hong Kong Intellectual Property Department issues guidelines aligning with EPC practices, emphasizing detailed disclosures.
4. What strategies improve patent enforceability for biopharmaceutical inventions?
Draft claims with specific molecular details, comprehensive descriptions, and clear method steps.
5. Can secondary uses of known drugs be patented in Hong Kong?
Yes, if the new use involves inventive steps and is novel, novelty can be established for therapeutic indications.
References
[1] Hong Kong Patent Ordinance, Cap. 514.
[2] Hong Kong Intellectual Property Department Patent Examination Guidelines.
[3] European Patent Convention, Articles 52–57.
